Table 1B.

Social cognitive performance (mean±S.D.) before pre-single dose administration and after one-week follow-up for placebo and oxytocin treatment groups

Social cognition Test	Placebo Nasal Spray			Oxytocin Nasal Spray			Overall
	Pre-single dose administration	One-week Follow-Up	Mean difference	Pre-single dose administration	One-week Follow-Up	Mean difference	Partial Eta Squared	90% Confidence Interval	F (1,6)	p
RMET, raw score	27.0±1.8	25.8±5.3	-1.2	27.5±1.7	27.0±2.9	-0.5	0.01	0.00-0.28	0.09	0.78
FSAR, total	18.5±8.8	21.5±4.7	3.0	20.5±2.4	23.3±3.4	2.8	0.00	-	0.00	0.96
FSAR, mean speed	7.9±1.7	8.1±0.5	-0.2	7.9±0.9	8.1±1.3	-0.2	0.00	-	0.00	0.96
EET	17.8±4.7	16.8±5.4	-1.0	18.0±5.0	15.5±3.9	-2.5	0.05	0.00-0.36	0.34	0.58
EDT	16.5±2.4	16.0±2.4	-0.5	15.8±3.2	14.8±4.0	-1.0	0.04	0.00-0.34	0.23	0.65

RMET, Reading the Mind in the Eyes Test; FSAR, Facial Speed and Recognition Task; EET, Emotion Evaluation Test; EDT, Emotion Discrimination Test.